全文获取类型
收费全文 | 18466篇 |
免费 | 1955篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 151篇 |
儿科学 | 628篇 |
妇产科学 | 648篇 |
基础医学 | 2604篇 |
口腔科学 | 355篇 |
临床医学 | 2159篇 |
内科学 | 3750篇 |
皮肤病学 | 185篇 |
神经病学 | 1409篇 |
特种医学 | 518篇 |
外科学 | 2582篇 |
综合类 | 562篇 |
一般理论 | 43篇 |
预防医学 | 2277篇 |
眼科学 | 293篇 |
药学 | 1363篇 |
中国医学 | 15篇 |
肿瘤学 | 895篇 |
出版年
2021年 | 312篇 |
2020年 | 197篇 |
2019年 | 297篇 |
2018年 | 322篇 |
2017年 | 260篇 |
2016年 | 240篇 |
2015年 | 272篇 |
2014年 | 404篇 |
2013年 | 616篇 |
2012年 | 832篇 |
2011年 | 937篇 |
2010年 | 488篇 |
2009年 | 458篇 |
2008年 | 757篇 |
2007年 | 802篇 |
2006年 | 744篇 |
2005年 | 788篇 |
2004年 | 708篇 |
2003年 | 695篇 |
2002年 | 657篇 |
2001年 | 595篇 |
2000年 | 633篇 |
1999年 | 542篇 |
1998年 | 243篇 |
1997年 | 203篇 |
1996年 | 222篇 |
1995年 | 199篇 |
1994年 | 162篇 |
1993年 | 157篇 |
1992年 | 433篇 |
1991年 | 476篇 |
1990年 | 442篇 |
1989年 | 406篇 |
1988年 | 351篇 |
1987年 | 381篇 |
1986年 | 350篇 |
1985年 | 337篇 |
1984年 | 281篇 |
1983年 | 238篇 |
1982年 | 150篇 |
1981年 | 142篇 |
1979年 | 192篇 |
1978年 | 144篇 |
1977年 | 148篇 |
1976年 | 122篇 |
1974年 | 182篇 |
1973年 | 163篇 |
1972年 | 131篇 |
1971年 | 115篇 |
1970年 | 133篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
Peter B. Arnold Chris A. Campbell George Rodeheaver Wyndell Merritt Raymond F. Morgan David B. Drake 《Hand (New York, N.Y.)》2009,4(3):302-307
The purpose of this study was to demonstrate that perivascularly applied botulinum toxin-A (BTX) increases the diameter of
treated blood vessels in a rat femoral vessel exposure model. Six adult Sprague–Dawley rats were used and bilateral femoral
artery and vein exposures were performed. Five units of BTX were applied to the experimental side and an equal volume of sterile
saline was applied to the control side. Digital images of the vessels were obtained at the following time points: pretreatment,
immediately posttreatment, and postoperative days (POD) 1, 14, and 28. Vessel diameters were equivalent at baseline and immediately
following application of BTX and saline. The BTX artery was significantly larger than the control artery on POD 1 and 14.
The BTX treated artery was significantly larger than all other vessels on POD 14 (p < 0.05) as well as all prior time points (p < 0.01). Direct perivascular application of BTX increases the diameter of rat femoral vessels as early as POD 1. The affect
is most robust on POD 14 where the artery was significantly larger than all other vessels at all time points. It is likely
that the increased diameter of blood vessels results in an increased blood flow across the area of dilation. Such an increase
in flow may serve to improve end-organ perfusion in microvascular procedures. 相似文献
23.
Gary D. Pipes Phillip Campbell Pavel V. Bondarenko Bruce A. Kerwin Michael J. Treuheit Himanshu S. Gadgil 《Journal of pharmaceutical sciences》2010,99(11):4469-4476
A middle-down LC/MS approach, for the rapid quantitation and characterization of site-specific methionine oxidation in a recombinant monoclonal IgG1 molecule, is described. An IgG1 antibody was digested with endoprotease LysC under limited proteolytic conditions to produce two major components; an antigen binding fragment (Fab) and a crystallizable fraction (Fc). These fractions were then reduced to produce three major species; light chain (LC), Fc/2 which is the C terminal region of the heavy chain (HC) and the N-terminal heavy chain region (Fd). These three fragments were separated by reversed-phase HPLC using a diphenyl column. The diphenyl column resolved site-specific methionine oxidation in all three subunits. Middle- down N-terminal sequencing with a LCT premier mass spectrometer was used to identify the sites of oxidation in the LC. Sites of oxidation in the Fc/2 were identified using middle-down collision-induced dissociation (CID) on a Qtof premier. This method allowed for the rapid quantitation and identification of oxidation on each methionine residue in an IgG1 molecule. 相似文献
24.
25.
E. B. Austin F. Thistlethwaite S. Neeson P. Stern L. McDonald M. Hulston D. Gilham E. Elkord R. Griffiths R. Guest J. D. M. Campbell R. E. Hawkins 《Transfusion medicine (Oxford, England)》2006,16(Z1):8-8
The CXCL12/CXCR4 chemokine axis is a well characterized and important chemotactic stimulus/receptor unit that orchestrates the homing and migration of cells to the bone marrow and to ischemic tissues following tissue damage. Here, we demonstrate that the sialomucin, CD164, a regulator of haemopoietic precursor cell adhesion to stroma and entry of primitive CD34+CD38lo/‐ precursor cells into cycle, modulates the migration of CD133+ cord blood cells to CXCL12 by associating with the CXCR4 receptor. This was demonstrated by a reduction in CD133+ cell migration on fibronectin to CXCL12 (i) by engaging the functional class II glycosylation‐dependent epitope on CD164 with the 103B2/9E10 class II but not the N6B6 class III antibody; and (ii) by RNAi knockdown of CD164 protein levels in CD133+ cells. The inhibition of migration was more pronounced in the more primitive CD34+CD38lo/‐ cell subset. Similar studies using the Jurkat cell line confirmed these findings and led to further analyses using alternative chemokines. A direct association between CXCR4 and CD164 was demonstrated by the co‐localisation of CD164 with CXCR4 and VLA‐4 and VLA‐5 at the leading edge of CD133+ cells when CXCL12 was presented on fibronectin. This was further supported by immunoprecipitation studies that demonstrate in the absence of CXCL12, CXCR4 is associated only with VLA‐4 and VLA‐5 but on exposure to CXCL12, CD164 is rapidly recruited to the CXCR4 complex. Knock‐down of CD164 using siRNA revealed that signalling through CXCR4 via PKC‐ζ was significantly dampened. Our findings therefore support a novel association between three distinct families of cell surface receptors that regulate both cell migratory and proliferative responses and identify a CD164 as a key regulator of the CXCL12/CXCR4 axis. 相似文献
26.
For the management of a condition such as asthma, patients should feel confident with their medication, feel that the treatment is adequate in controlling symptoms and that side-effects of the treatment are minimal. As no comprehensive instrument to measure patient satisfaction with inhaled asthma medication existed, the Satisfaction with Asthma Treatment Questionnaire was developed. The procedures that were used are described, and the initial validation and reliability tests are reported. The study involved focus group meetings, development, testing and modification of a preliminary instrument, and testing of the revised instrument using different samples of patients with asthma. Factor analysis of the 26-item questionnaire identified four domains reflecting four aspects of satisfaction: effectiveness of treatment, ease of use, medication burden, and side-effects and worries. Cronbach's alpha showed evidence of internal consistency reliability. Test/retest reliability ranged from 0.66-0.74. Interscale correlations were moderate-to-high. Significant correlations were found between domain and overall scale scores and patients' overall level of satisfaction. The Satisfaction with Asthma Treatment Questionnaire is potentially a useful instrument for gaining insight into patient satisfaction with inhaled treatment for asthma. 相似文献
27.
28.
29.
E. Winslow J. K. Campbell L. Delbressine 《The Journal of pharmacy and pharmacology》1995,47(7):608-613
Org 20781, the major metabolite of Org 7797 found in in-vitro experiments was examined for antiarrhythmic and electrophysiological effects in-vivo. Org 20781 (0·5–2·0 mg kg?1 i.v.) inhibited the development of early ischaemia-induced arrhythmias in rats, suppressed spontaneous ventricular tachycardia (VT) in conscious dogs with 24-h old infarcts, and prevented electrical induction of VT in dogs with 5–6-day old infarcts, actions associated with slowing of conduction at all levels of the myocardium. Cardiac refractory periods were only modestly prolonged whilst repolarization was unchanged. Peak plasma levels of the parent compound (infused to total doses of 2–4mg kg?1) associated with suppression of late arrhythmias were 6–18 μm, whilst the mean plasma elimination half-life (in normal dogs) was 107 min. It was concluded that the major metabolite has a similar antiarrhythmic and electrophysiological profile to the parent compound, is at least half as potent and may contribute to the therapeutic effects of Org 7797 administration. 相似文献
30.